Login to Your Account

Financings NEWS

Quietly launched three years ago, Blackthorn Therapeutics Inc. declared its intention to tackle neurobehavioral disorders in a big way, closing a $40 million series A.

DUBLIN – Crispr Therapeutics AG pulled in $56 million in an IPO on Nasdaq, alongside a concurrent private placement with strategic partner Bayer AG, which raised another $35 million. The combined transactions take the company’s total funding raised from inception to $384.4 million, including private and public equity investment, convertible loans and collaboration revenues.

DUBLIN – Ogeda SA, the company formerly known as Euroscreen SA, celebrated its change of moniker with a €2 million (US$2.2 million) add-on to its series B round, taking the total to €18 million (US$20 million).

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: